Cyril Pottier, PhD

Identifying genetic risk factors and modifiers of early onset Alzheimer’s disease and related dementias

Alzheimer’s disease—the most common neurodegenerative disorder worldwide—is characterized by episodic memory impairment, with early onset Alzheimer’s disease (EOAD) patients experiencing initial symptoms before the age of 65. Despite great progress in the field, most patients remain genetically unexplained, advocating for the use of a variety of innovative and integrative methodologies. Moreover, significant clinical heterogeneity is observed, even among patients carrying the same mutation, strongly suggesting the contribution of genetic modifiers in disease etiology. My research program aims at identifying
disease associated genomic events that may serve as both therapeutic targets and biomarkers for EOAD and Alzheimer’s disease related dementias.

More about Cyril Pottier

---